[
  {
    "ts": null,
    "headline": "The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease",
    "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Aβ monoclonal antibody lecanemab, adopted in November 2024.1 Following CHMP's reaffirmation, after having considered the additional inform",
    "url": "https://finnhub.io/api/news?id=67d5571436f76834b82eaa99ac7df2d7ed6d3c15ff9c1f4f575ea7ae7fc4d07a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740748980,
      "headline": "The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease",
      "id": 133191256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Aβ monoclonal antibody lecanemab, adopted in November 2024.1 Following CHMP's reaffirmation, after having considered the additional inform",
      "url": "https://finnhub.io/api/news?id=67d5571436f76834b82eaa99ac7df2d7ed6d3c15ff9c1f4f575ea7ae7fc4d07a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen, Eisai : CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
    "summary": "By Colin Kellaher Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi....",
    "url": "https://finnhub.io/api/news?id=be78faba6a29d22c37f5d1fe51c42446080a58ce0bfea13271def4feeafd7b4e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740737298,
      "headline": "Biogen, Eisai : CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
      "id": 132905813,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi....",
      "url": "https://finnhub.io/api/news?id=be78faba6a29d22c37f5d1fe51c42446080a58ce0bfea13271def4feeafd7b4e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
    "summary": "Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
    "url": "https://finnhub.io/api/news?id=ae068a80e66ed4412af28fdede036c89edc9efa1912c8261f048e45d500fc1de",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740736320,
      "headline": "Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
      "id": 132922082,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug",
      "url": "https://finnhub.io/api/news?id=ae068a80e66ed4412af28fdede036c89edc9efa1912c8261f048e45d500fc1de"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease",
    "summary": "TOKYO and CAMBRIDGE, Mass., February 28, 2025 - Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...",
    "url": "https://finnhub.io/api/news?id=9eb307e4db3dfa9c42f14ffc0a0fe75e28c9d0eb255d91053ff3bd8f88e257d1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740731444,
      "headline": "Biogen : The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease",
      "id": 132905223,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "TOKYO and CAMBRIDGE, Mass., February 28, 2025 - Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...",
      "url": "https://finnhub.io/api/news?id=9eb307e4db3dfa9c42f14ffc0a0fe75e28c9d0eb255d91053ff3bd8f88e257d1"
    }
  },
  {
    "ts": null,
    "headline": "EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes",
    "summary": "The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status....",
    "url": "https://finnhub.io/api/news?id=5ab8089bc309eab58ee5a9e4dfdbddc3b1c7dd726beb7a05c9750c56c0b42e9a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740730618,
      "headline": "EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes",
      "id": 132905146,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status....",
      "url": "https://finnhub.io/api/news?id=5ab8089bc309eab58ee5a9e4dfdbddc3b1c7dd726beb7a05c9750c56c0b42e9a"
    }
  },
  {
    "ts": null,
    "headline": "EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug",
    "summary": "European Union's human medicines committee said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November. ...",
    "url": "https://finnhub.io/api/news?id=1a04df2d01d1d8b5cc07f2ab62407287e96a0ef46fc3076f5eb5d5f261ff8834",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740729289,
      "headline": "EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug",
      "id": 132904969,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "European Union's human medicines committee said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November. ...",
      "url": "https://finnhub.io/api/news?id=1a04df2d01d1d8b5cc07f2ab62407287e96a0ef46fc3076f5eb5d5f261ff8834"
    }
  },
  {
    "ts": null,
    "headline": "Under The Microscope: Looking For Opportunity Among Healthcare's Underperformers",
    "summary": "Many stocks in the healthcare sector have trailed the wider markets, but are there pockets of opportunity? TD Asset Management's Ram Sampath discusses.",
    "url": "https://finnhub.io/api/news?id=ee89c0cbe9506e056ebf3d083277e9ebea494a171c6235d0e9374fc1537447f6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740720000,
      "headline": "Under The Microscope: Looking For Opportunity Among Healthcare's Underperformers",
      "id": 132904137,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Many stocks in the healthcare sector have trailed the wider markets, but are there pockets of opportunity? TD Asset Management's Ram Sampath discusses.",
      "url": "https://finnhub.io/api/news?id=ee89c0cbe9506e056ebf3d083277e9ebea494a171c6235d0e9374fc1537447f6"
    }
  }
]